Drug Profile
JNJ 18054478
Latest Information Update: 01 Sep 2009
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Antiasthmatics
- Mechanism of Action Chymase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 04 Sep 2007 Phase-I clinical trials in Asthma in USA (PO)
- 16 Jan 2007 Preclinical trials in Asthma in USA (unspecified route)